Navigation Links
BioTech Holdings Announces First Clinical Use of Microbiome Optimized Autologous Stem Cells
Date:7/7/2017

SAN DIEGO, July 7, 2017 /PRNewswire/ -- BioTech Holdings announced today clinical safety data on 3 patients suffering from critical limb ischemia treated with the Company's Procell microbiome-optimized personalized stem cell product. 

In the investigator initiated pilot study, patients with diabetes associated circulation deficit in the legs (critical limb ischemia), who failed previous treatments were administered their own bone marrow derived stem cells that were treated with the Company's proprietary microbiome-derived compounds. 

No treatment associated adverse reactions were observed and patients were followed-up for 3 months.  Furthermore, 2 of the 3 patients had documented improvement in leg circulation and healing of previously unhealing ulcers.

"It is well known that the microbiome controls many aspects of human health and disease ranging from obesity, to autoimmunity, to even neurological function," said Thomas E Ichim, Ph.D, President and CEO of Biotech Holdings. "We are fortunate to have filed intellectual property on application of probiotics and microbiome manipulation to stem cells more than a year ago1.  The current study supports our forward movement of our ProCell product to formal clinical trials."

The Company's product, Procell, comprises of bone marrow stem cells from the same patient, that are treated with factors generated by the microbiome of healthy patients. The key ingredient that the company has identified as secreted by the microbiome which augments stem cell activity is already approved by the FDA for other indications. Accordingly, the company believes it is eligible for accelerated FDA registration pathways, including the 505b2 pathway.

The Company intends to develop the indication of critical limb ischemia as its first condition. Patients with this conditions have a major amputation rate as high as 40% at 6 months and a mortality rate of 20% to 25% in the first year after presentation. Critical limb ischemia represents a market of approximately 10 billion dollar per year2.

Contacts

Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121
167146@email4pr.com 
858 353 4303
Twitter: @biotechholdings

1 http://www.prnewswire.com/news-releases/biotech-holdings-announces-positive-preclinical-results-on-procell-probiotic-cell-therapy-for-critical-limb-ischemia-300278136.html

2 http://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-January-2017.pdf

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biotech-holdings-announces-first-clinical-use-of-microbiome-optimized-autologous-stem-cells-300484814.html


'/>"/>
SOURCE Biotech Holdings
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Founders of Philadelphia Biotech Enterin Inc. Discover Link Between Upper GI Tract Infections and Parkinsons Disease
2. Kibow Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics
3. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
4. Greater Gainesville Region Advances as Florida’s Leading Location for Biotech Incubation and Technology Transfer
5. Pathway for Veterans into the Biotech Industry
6. UConn Innovation Fund Provides First Round Funding to Three Biotech Startups
7. Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
8. Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
9. Superior Controls and Banks Integration Group Merge, Creating Industry-Leading Biotech System Integration Company
10. iPath Media and DoyleCreek Strategic Communications Join Forces to Offer New Marketing Services to Pharmaceutical and Biotech Companies
11. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):